Chronic Lymphocytic Leukemia

In an interview with Targeted Oncology following the tweet chat, Cyrus M. Khan, MD, discussed the emerging and recent data he thinks could influence the case we discussed.

A 5-year overall survival analysis led the FDA to question duvelisib for relapsed or refractory chronic lymphocytic leukemia. ODAC members voted that the benefit-risk profile of the drug is not favorable.

Doctors and patients who can stick with a regimen despite relatively minor adverse event will ultimately have more options later in the treatment journey, which could then lead to better long-term outcomes in chronic lymphocytic leukemia.

Wojciech Jurczak, MD, PhD, discusses the available treatment options for patients with relapsed/refractory chronic lymphocytic leukemia who relapsed on BCL2 inhibitors.

Data from the planned interim analysis of the FLAIR trial show that venetoclax plus ibrutinib can achieved minimal residual disease negativity in patient with treatment-naïve chronic lymphocytic leukemia.

Wojciech Jurczak, MD, PhD, discussed the results of the clinical trial investigation of ceralasertib with or without acalabrutinib in patients with high-risk relapsed/refractory chronic lymphocytic leukemia.

Acalabrutinib’s new tablet formulation has been granted FDA approval for all current indications, including adult patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and relapsed or refractory mantle cell lymphoma.

In the first comparison of zanubrutinib vs chemoimmunotherapy, zanbrutinib was shown to improve progression-free survival in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, and may be less toxic.

Mazyar Shadman, MD, MPH, discusses the results of his research on MB-106 as treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

During a Targeted Oncology case-based roundtable event, Jan A. Burger, MD, PhD, discussed data supporting the use of ibrutinib, acalabrutinib, and zanubrutinib for first-line treatment of chronic lymphocytic leukemia.

Findings from an analysis of the CAPTIVATE study imply that ibrutinib plus venetoclax may allow for effective subsequent retreatment with ibrutinib and/or venetoclax and enhance clinical benefit.

During a Targeted Oncology case-based roundtable event, John N. Allan, MD, discussed the factors for choosing treatment for chronic lymphocytic leukemia with a Bruton tyrosine kinase inhibitor.

Mazyar Shadman, MD, MPH, discusses the phase 1/2 clinical trial of MB-106 for patients with CD20 positive B-cell malignancies.

During a Targeted Oncology case-based roundtable event, Susan O'Brien, MD, discussed the case of a 71-year-old woman newly diagnosed with chronic lymphocytic leukemia.

Nakhle Saba, MD, discusses the significance of the key findings of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for patients with chronic lymphocytic leukemia.

With roughly 5 years of follow-up, outcomes were more favorable with acalabrutinib with or without obinutuzumab vs obinutuzumab and chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia.

John F. Seymour, MBBS, PhD, discusses the results of a post-hoc analysis of adverse events in the phase 3 ELEVATE-RR trial comparing acalabrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Nakhle Saba, MD, reviewed testing, treatment, and treatment toxicity in a 71-year-old woman with chronic lymphocytic leukemia with a group of peers during a Targeted Oncology case-based roundtable event.

Dosing of NX-2127 in patients with chronic lymphocytic leukemia has begun in a phase 1b clinical trial.

Catherine Coombs, MD, MS, shares her thoughts on the future of treatment and where the field is moving for patients with CLL.

A detailed description of emerging treatment options for patients with relapsed/refractory CLL.

Catherine Coombs, MD, MS, highlights available data and considerations for retreatment with venetoclax in the relapsed/refractory setting.

A comprehensive review of existing second-line treatment options for patients with R/R CLL.

Catherine Coombs, MD, MS, reviews factors that impact the selection of treatment in patients with CLL.

An expert in treating CLL discusses potential treatment options for a patient with relapsed/refractory CLL who has been previously treated with venetoclax plus obinutuzumab.